These results were consistent with in vivo studies in immunodeficient mice, which showed a significant decrease in Pgp+ tumor weight when treated with a combination of doxorubicin and UIC2 compared with doxorubicin alone [84]. This evidence concerns the gene PGP and neoplasm.